ANI Pharmaceuticals, Inc. (ANIP)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$70.70+0.67%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Intact: The reason to own it still holds.
ANI grows Cortrophin Gel revenue to at least $540 million in 2026. Rare Disease sales make up about 60% of total revenue. The company raised its 2026 EPS guidance to about $9.44 per share. Profit margins are steady near 60%.
Quality control problems may slow Cortrophin Gel sales growth. Revenue could fall below $540 million. Rare Disease expansion may stall. EPS might miss the raised guidance.
The price is about 40% below our fair value near $143. Analysts expect nearly 20% revenue decline, which is more pessimistic than our view.
Breaks if: Cortrophin Gel revenue falls below $540 million in 2026
Focus on maximizing multi-year growth opportunities for Cortrophin Gel across various indications.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth in the Cortrophin Gel market and a stable generics business. The current thesis state is intact, supported by strong financial performance and management execution.
Valuation is considered stretched compared to peers, indicating that the market has high expectations for ANIP's continued growth. The expectations gap suggests that some growth is already factored into the current valuation.
Fundamentals are likely to show continued strength, especially in the Cortrophin Gel segment, which has seen robust revenue growth. However, the mixed progress in the Rare Disease portfolio and ILUVIEN may pose challenges in the near term.
The thesis hinges on management's ability to maintain guidance and deliver on growth initiatives, particularly if sector peers continue to perform well. Additionally, macroeconomic factors, such as job growth and recession fears, could impact performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that would weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS falls below $9.19 in 2026
Breaks if: Gross margin falls below 59.3% in 2026
Breaks if: Rare Disease revenue share falls well below 60% in 2026
Overall, ANIP's outlook is supported by strong management and recent performance, but it faces risks that could affect its trajectory. Not investment advice.